Atoltivimab

Names

[ Name ]:
Atoltivimab

Biological Activity

[Description]:

Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and Drug Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection[1].

[Related Catalog]:

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> Filovirus

[Target]

Ebolaviru (EBOV)[1]

[References]

[1]. Saxena D, et al. Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus. Drugs Today (Barc). 2021 Aug;57(8):483-490.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.